Annexon (ANNX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.41, -5.28% vs the prior close of $3.60.
- Volume 5.24M shares, 1.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ANNX slides 5.3% to $3.41, a 6-month low, 5 down days in a row. Closed at $3.41, -5.28% vs the prior close of $3.60. Day range $3.36–$3.61, opened at $3.60.
ANNX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ANNX slides 5.3% to $3.41, a 6-month low, 5 down days in a row
- Closed at $3.41, -5.28% vs the prior close of $3.60. Day range $3.36–$3.61, opened at $3.60.
- Volume was 5.24M shares, 1.8x its 50-day average of 2.98M.
- Price is -24.1% vs its 50-day average ($4.49) and -35.6% vs its 200-day average ($5.30).
- 52-week range $2.54–$7.18; today's close sits at 19% of that range, 52.5% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — ANNX dips 1.9% to $3.60, a 6-month low, 4 down days in a row
- Closed at $3.60, -1.91% vs the prior close of $3.67. Day range $3.50–$3.82, opened at $3.70.
- Volume was 2.65M shares, 0.9x its 50-day average of 2.96M.
- Price is -20.6% vs its 50-day average ($4.53) and -32.2% vs its 200-day average ($5.31).
- 52-week range $2.54–$7.18; today's close sits at 23% of that range, 49.9% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — ANNX slides 4.2% to $3.67, 3 down days in a row
- Closed at $3.67, -4.18% vs the prior close of $3.83. Day range $3.66–$3.85, opened at $3.79.
- Volume was 4.04M shares, 1.4x its 50-day average of 2.93M.
- Price is -19.7% vs its 50-day average ($4.57) and -30.9% vs its 200-day average ($5.31).
- 52-week range $2.54–$7.18; today's close sits at 24% of that range, 48.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ANNX slides 3.3% to $3.83
- Closed at $3.83, -3.28% vs the prior close of $3.96. Day range $3.78–$3.96, opened at $3.96.
- Volume was 3.42M shares, 1.2x its 50-day average of 2.91M.
- Price is -16.8% vs its 50-day average ($4.60) and -28.0% vs its 200-day average ($5.32).
- 52-week range $2.54–$7.18; today's close sits at 28% of that range, 46.7% below the 52-week high.
Oct 12, 2026 — ANNX dips 1.5% to $3.96
- Closed at $3.96, -1.49% vs the prior close of $4.02. Day range $3.95–$4.05, opened at $4.02.
- Volume was 1.93M shares, 0.7x its 50-day average of 2.93M.
- Price is -14.5% vs its 50-day average ($4.63) and -25.7% vs its 200-day average ($5.33).
- 52-week range $2.54–$7.18; today's close sits at 31% of that range, 44.8% below the 52-week high.
Oct 9, 2026 — ANNX rises 0.5% to $4.02
- Closed at $4.02, +0.50% vs the prior close of $4.00. Day range $3.97–$4.14, opened at $3.97.
- Volume was 2.38M shares, 0.8x its 50-day average of 2.94M.
- Price is -13.6% vs its 50-day average ($4.65) and -24.6% vs its 200-day average ($5.33).
- 52-week range $2.54–$7.18; today's close sits at 32% of that range, 44.0% below the 52-week high.
Oct 8, 2026 — ANNX ends flat (-0.2%) to $4.00, 3 down days in a row
- Closed at $4.00, -0.25% vs the prior close of $4.01. Day range $3.86–$4.03, opened at $3.99.
- Volume was 3.21M shares, 1.1x its 50-day average of 2.94M.
- Price is -14.5% vs its 50-day average ($4.68) and -25.1% vs its 200-day average ($5.34).
- 52-week range $2.54–$7.18; today's close sits at 31% of that range, 44.3% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — ANNX dips 0.5% to $4.01
- Closed at $4.01, -0.50% vs the prior close of $4.03. Day range $3.91–$4.18, opened at $3.99.
- Volume was 2.45M shares, 0.8x its 50-day average of 2.94M.
- Price is -14.6% vs its 50-day average ($4.70) and -25.0% vs its 200-day average ($5.35).
- 52-week range $2.54–$7.18; today's close sits at 32% of that range, 44.2% below the 52-week high.
Oct 6, 2026 — ANNX slides 4.0% to $4.03
- Closed at $4.03, -4.05% vs the prior close of $4.20. Day range $4.01–$4.26, opened at $4.21.
- Volume was 2.70M shares, 0.9x its 50-day average of 2.92M.
- Price is -14.5% vs its 50-day average ($4.72) and -24.7% vs its 200-day average ($5.35).
- 52-week range $2.54–$7.18; today's close sits at 32% of that range, 43.9% below the 52-week high.
Oct 5, 2026 — ANNX ends flat (+0.2%) to $4.20
- Closed at $4.20, +0.24% vs the prior close of $4.19. Day range $4.06–$4.31, opened at $4.25.
- Volume was 3.45M shares, 1.2x its 50-day average of 2.91M.
- Price is -11.3% vs its 50-day average ($4.74) and -21.5% vs its 200-day average ($5.35).
- 52-week range $2.54–$7.18; today's close sits at 36% of that range, 41.5% below the 52-week high.
Oct 2, 2026 — ANNX rises 1.7% to $4.19
- Closed at $4.19, +1.70% vs the prior close of $4.12. Day range $4.11–$4.26, opened at $4.21.
- Volume was 4.02M shares, 1.4x its 50-day average of 2.87M.
- Price is -11.9% vs its 50-day average ($4.76) and -21.8% vs its 200-day average ($5.36).
- 52-week range $2.54–$7.18; today's close sits at 36% of that range, 41.6% below the 52-week high.
ANNX latest news & SEC filings
Every SEC filing by or about ANNX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Love Douglas bought 26,065 shares at $3.83 (≈$99.83K) on Sep 24, 2026; now holds 390,476
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 12, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$55.35M (prior year -$49.16M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.28 (prior year -$0.34) (loss narrowed vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 8.01 — Reported other events the company considers important.
Jul 27, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade ANNX
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 30, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.81% (largest 10.2%).
- Liquidity: about 3.34M shares (≈$11.38M) trade per day on average.
- 52-week position: $3.41 vs a range of $2.54–$7.18 (19% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 20 open-market buys, 5 sales; latest: Douglas Love bought 26,065 shares on Sep 24, 2026.
- Latest filings: 10-Q Aug 12, 2026; 8-K Aug 12, 2026; 8-K Aug 10, 2026.
- Share count: 38.56M shares outstanding (May 2, 2022), +0.8% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ANNX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.60 | 3.61 | 3.36 | 3.41 | 5.24M |
| Oct 15, 2026 | 3.70 | 3.82 | 3.50 | 3.60 | 2.65M |
| Oct 14, 2026 | 3.79 | 3.85 | 3.66 | 3.67 | 4.04M |
| Oct 13, 2026 | 3.96 | 3.96 | 3.78 | 3.83 | 3.42M |
| Oct 12, 2026 | 4.02 | 4.05 | 3.95 | 3.96 | 1.93M |
| Oct 9, 2026 | 3.97 | 4.14 | 3.97 | 4.02 | 2.38M |
| Oct 8, 2026 | 3.99 | 4.03 | 3.86 | 4.00 | 3.21M |
| Oct 7, 2026 | 3.99 | 4.18 | 3.91 | 4.01 | 2.45M |
| Oct 6, 2026 | 4.21 | 4.26 | 4.01 | 4.03 | 2.70M |
| Oct 5, 2026 | 4.25 | 4.31 | 4.06 | 4.20 | 3.45M |
| Oct 2, 2026 | 4.21 | 4.26 | 4.11 | 4.19 | 4.02M |
| Oct 1, 2026 | 4.18 | 4.38 | 4.12 | 4.12 | 3.92M |
| Sep 30, 2026 | 4.19 | 4.27 | 4.05 | 4.23 | 4.41M |
| Sep 29, 2026 | 4.00 | 4.24 | 3.94 | 4.13 | 3.71M |
| Sep 28, 2026 | 3.85 | 4.08 | 3.73 | 4.01 | 5.07M |
| Sep 25, 2026 | 3.81 | 3.85 | 3.63 | 3.64 | 3.51M |
| Sep 24, 2026 | 3.85 | 3.87 | 3.72 | 3.80 | 2.02M |
| Sep 23, 2026 | 4.18 | 4.19 | 3.81 | 3.87 | 2.42M |
| Sep 22, 2026 | 4.28 | 4.34 | 4.13 | 4.18 | 2.00M |
| Sep 21, 2026 | 4.27 | 4.36 | 4.12 | 4.22 | 4.18M |
About Annexon
Annexon (ANNX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BRISBANE, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1528115.
ANNX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Mark S. Blumenkranz | Director | Aug 12, 2026 |
| William H. Carson | Director | Jun 15, 2026 |
| Jung Choi | Director | Jun 15, 2026 |
| Bettina M. Cockroft | Director | Jun 15, 2026 |
| William A Jr Jones | Director | Jun 15, 2026 |
| Douglas Love | PRESIDENT AND CEO | Sep 25, 2026 |
| Muneer A Satter | Director | Jun 15, 2026 |
| William D. Waddill | Director | Jun 15, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Dean Richard Artis | EVP & CHIEF SCIENTIFIC OFFICER | Mar 4, 2026 |
| Jamie Dananberg | CHIEF MEDICAL OFFICER | Mar 4, 2026 |
| Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | Mar 4, 2026 |
| Douglas Love | PRESIDENT AND CEO | Sep 25, 2026 |
| Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | Mar 4, 2026 |
| Ted Yednock | EVP & CHIEF INNOVATION OFFICER | Jun 15, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 24, 2026 | Douglas Love | Buy | 26,065 | $3.83 |
| Sep 24, 2026 | Douglas Love | Buy | 26,065 | $3.83 |
| Sep 24, 2026 | Douglas Love | Buy | 26,065 | $3.83 |
| Sep 24, 2026 | Douglas Love | Buy | 26,065 | $3.83 |
| May 28, 2026 | Muneer A Satter | Buy | 613,497 | $5.41 |
| May 28, 2026 | Muneer A Satter | Buy | 613,497 | $5.41 |
| May 28, 2026 | Muneer A Satter | Buy | 613,497 | $5.41 |
| May 28, 2026 | Muneer A Satter | Buy | 613,497 | $5.41 |
| May 11, 2026 | William H. Carson | Buy | 8,000 | $5.78 |
| May 11, 2026 | William H. Carson | Buy | 8,000 | $5.78 |
| May 11, 2026 | William H. Carson | Buy | 8,000 | $5.78 |
| May 11, 2026 | William H. Carson | Buy | 8,000 | $5.78 |
| Apr 10, 2026 | William H. Carson | Buy | 8,000 | $6.20 |
| Apr 10, 2026 | William H. Carson | Buy | 8,000 | $6.20 |
| Apr 10, 2026 | William H. Carson | Buy | 8,000 | $6.20 |
ANNX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-206.69M | -1.34 | $-186.36M |
| Dec 31, 2024 | — | $-138.20M | -1.01 | $-118.01M |
| Dec 31, 2023 | — | $-134.24M | -1.77 | $-121.14M |
| Dec 31, 2022 | — | $-141.95M | -2.60 | $-116.31M |
| Dec 31, 2021 | — | $-130.32M | -3.40 | $-106.11M |
Latest balance sheet: total assets $246.07M, total liabilities $60.01M, cash $199.27M (as of Jun 30, 2026).
ANNX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $5.33 |
| May 7, 2026 | 8-K Item 2.02 (results) | $5.52 |
| Mar 30, 2026 | 8-K Item 2.02 (results) | $4.96 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $2.98 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $2.38 |
| May 12, 2025 | 8-K Item 2.02 (results) | $1.77 |
| Mar 3, 2025 | 8-K Item 2.02 (results) | $2.39 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $6.33 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Mar 26, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ANNX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.